Market Overview

Jefferies Raises Price Target On Cubist Pharmaceuticals

Related CBST
Stocks Hitting 52-Week Highs
State Of The Union Lights Up Biotech

In a research note released Monday, Jefferies analyst Eun K. Yang increased his price target on Cubist Pharmaceuticals (NASDAQ: CBST)from $87 to $88.

The increase in the price target was primarily based on the Food and Drug Administration's approval of Sivextro.

The analyst is expecting shares to appreciate as the company starts to release its drug. In addition, as two more antibiotics are launching this year, the firm is expecting Cubist to improve its operating/profit margins in 2015.

Current quarter earnings per share estimates stand at $0.10, while current year estimates are $0.42.

Shares of Cubist are down two percent Monday.

Latest Ratings for CBST

Dec 2014UBSDowngradesBuyNeutral
Dec 2014RBC CapitalDowngradesOutperformSector Perform
Dec 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Eun K. Yang JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (CBST)

View Comments and Join the Discussion!